Noah Federman

8.8k total citations · 1 hit paper
142 papers, 3.0k citations indexed

About

Noah Federman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Noah Federman has authored 142 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pulmonary and Respiratory Medicine, 48 papers in Oncology and 38 papers in Molecular Biology. Recurrent topics in Noah Federman's work include Sarcoma Diagnosis and Treatment (56 papers), Neuroblastoma Research and Treatments (12 papers) and Bone Tumor Diagnosis and Treatments (12 papers). Noah Federman is often cited by papers focused on Sarcoma Diagnosis and Treatment (56 papers), Neuroblastoma Research and Treatments (12 papers) and Bone Tumor Diagnosis and Treatments (12 papers). Noah Federman collaborates with scholars based in United States, France and Denmark. Noah Federman's co-authors include Nicholas M. Bernthal, Fritz C. Eilber, William D. Tap, Scott D. Nelson, Catherine M. Albert, Theodore W. Laetsch, Christopher T. Denny, Jessica L. Davis, Kathleen M. Sakamoto and Leo Mascarenhas and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Cell.

In The Last Decade

Noah Federman

126 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

2018 378 citations Theodore W. Laetsch, Leo Mascarenhas et al. profile →

Peers

Countries citing papers authored by Noah Federman

Since Specialization

Citations

This map shows the geographic impact of Noah Federman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noah Federman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noah Federman more than expected).

Fields of papers citing papers by Noah Federman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noah Federman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noah Federman. The network helps show where Noah Federman may publish in the future.

Co-authorship network of co-authors of Noah Federman

This figure shows the co-authorship network connecting the top 25 collaborators of Noah Federman. A scholar is included among the top collaborators of Noah Federman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noah Federman. Noah Federman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial 2025 ·Journal of Clinical Oncology ·Ravin Ratan, Bernd Kasper, Thierry Alcindor, Patrick Schöffski, Winette T.A. van der Graaf, Noah Federman, Nam Q. Bui, Gina Z. D’Amato, Richard F. Riedel, Steven Attia, Sant P. Chawla, (unknown), (unknown), Ana B. Oton, (unknown), Shengfan Zhou, Mrinal M. Gounder	0
2	Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study. 2024 ·Journal of Clinical Oncology ·Bruno Vincenzi, Nam Bui, Palma Dileo, Noah Federman, Richard F. Riedel, Brian Andrew Van Tine, (unknown), Allison Lim, Ana B. Oton, Bernd Kasper	1
3	Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors 2024 ·Cancer Research ·Monica Mita, Alain C. Mita, Miguel A. Villalona‐Calero, Noah Federman, Drew Rasco, David R. Spigel, Jia Luo, Gregory M. Coté, Richard E. Cutler, Pavan Kumar, Crystal MacKenzie, Charles Y. Lin, Jorge DiMartino, Elizabeth Olek, Brian A. Van Tine	1
4	A signal-finding study of nivolumab and relatlimab in patients with advanced chordoma. 2024 ·Journal of Clinical Oncology ·(unknown), Arun S. Singh, Bartosz Chmielowski, (unknown), Noah Federman, (unknown), John A. Glaspy, (unknown), Lauren E. Wessel, Francis J. Hornicek, Nicholas M. Bernthal	2
5	Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma. 2024 ·Journal of Clinical Oncology ·Erlinda M. Gordon, Sant P. Chawla, (unknown), (unknown), (unknown), Vaishali Kumar, Neal Shiv Chawla, (unknown), Doris Quon, (unknown), Noah Federman	2
6	Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma 2024 ·Journal of Clinical Oncology ·Paul A. Meyers, Noah Federman, Najat C. Daw, Peter M. Anderson, Lara E. Davis, AeRang Kim, Margaret E. Macy, (unknown), Ravin Ratan, Richard F. Riedel, Matteo Trucco, James B. Breitmeyer, Jeffrey A. Toretsky, Joseph A. Ludwig	13
7	Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers 2024 ·Journal of Managed Care & Specialty Pharmacy ·(unknown), (unknown), (unknown), (unknown), Matthew B. Schabath, Jonathan P. Thompson, Jyoti Malhotra, Noah Federman, Gilbert Ko, (unknown), Neil D. Warnock, Sheldon X. Kong, (unknown), Diana Brixner, David D. Stenehjem	1
8	Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses. 2024 ·Journal of Clinical Oncology ·Bernd Kasper, Noah Federman, Peter Reichardt, Steven Attia, Allison Lim, (unknown), Sunny Cho, Richard F. Riedel	3
9	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300) 2023 ·Gynecologic Oncology ·Elizabeth Lee, Jordi Rodón, Michael J. Demeure, Dustin A. Deming, Noah Federman, Meredith McKean, Alexander I. Spira, David J. Kwiatkowski, Maen Hussein, Erlinda M. Gordon, David K. Crockett, Kristen N. Ganjoo, (unknown), Lee D. Cranmer, Anita Schmid, Willis H. Navarro, Loretta M. Itri, Gopa Iyer	1
10	Fibroblast Activation Protein Expression in Sarcomas 2023 ·Sarcoma ·Jacquelyn Crane, (unknown), Christine E. Mona, Scott D. Nelson, Alireza Samiei, David W. Dawson, Sarah Dry, (unknown), Joseph G. Crompton, Matthias Benz, Johannes Czernin, Fritz C. Eilber, Thomas G. Graeber, Jérémie Calais, Noah Federman	16
11	Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy 2023 ·JCO Precision Oncology ·(unknown), Trevor L. Hoffman, Kristiyana Kaneva, (unknown), (unknown), Megan P. Hitchins, Noah Federman	0
12	Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report 2023 ·Frontiers in Immunology ·(unknown), (unknown), Samuel W. French, Noah Federman, Theodore S. Nowicki	2
13	Long Term Survival Following DeltaRex-G/DeltaVax Tumor-Targeted Gene Therapy for Advanced Chemotherapy-Resistant Malignancies: An Academic Milestone 2021 ·Seiya Liu, Sant P. Chawla, Howard W. Bruckner, Michael A. Morse, Noah Federman, (unknown), (unknown), Jorge Ignacio, (unknown), (unknown), Erlinda M. Gordon	3
14	The Role of Social Media in Providing Support from Friends for Adolescent and Young Adult (AYA) Patients and Survivors of Sarcoma: Perspectives of AYA, Parents, and Providers 2021 ·Journal of Adolescent and Young Adult Oncology ·Elizabeth Donovan, Sarah R. Martin, Laura C. Seidman, Lonnie K. Zeltzer, Tara M. Cousineau, Laura A. Payne, (unknown), (unknown), Noah Federman	19
15	1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer 2020 ·Annals of Oncology ·Ray McDermott, Cornelis M. van Tilburg, Anna F. Farago, Shivaani Kummar, Daniel Shao-Weng Tan, Catherine M. Albert, Jordan Berlin, Ulrik Lassen, François Doz, Birgit Geoerger, Leo Mascarenhas, Noah Federman, (unknown), (unknown), Nicoletta Brega, (unknown), Theodore W. Laetsch, David S. Hong, Alexander Drilon	13
16	A Mobile-Based Mindfulness and Social Support Program for Adolescents and Young Adults With Sarcoma: Development and Pilot Testing 2019 ·JMIR mhealth and uhealth ·Elizabeth Donovan, Sarah R. Martin, Laura C. Seidman, Lonnie K. Zeltzer, Tara M. Cousineau, Laura A. Payne, (unknown), (unknown), (unknown), Noah Federman	33
17	TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening 2018 ·Journal of Clinical Oncology ·Catherine M. Albert, Jessica L. Davis, Noah Federman, Michela Casanova, Theodore W. Laetsch	66
18	5-Day Hypofractionated Preoperative Radiation Therapy in Soft Tissue Sarcoma: Preliminary Toxicity and Pathologic Outcomes from a Prospective Phase 2 Study 2017 ·International Journal of Radiation OncologyBiologyPhysics ·Anusha Kalbasi, Mitchell Kamrava, Scott D. Nelson, Sarah Dry, (unknown), Bartosz Chmielowski, Arun S. Singh, Noah Federman, Susan V. Bukata, Nicholas M. Bernthal, Michael L. Steinberg, Fritz C. Eilber	3
19	Safety and Efficacy of Stereotactic Body Radiation Therapy in the Treatment of Pulmonary Metastases from High Grade Sarcoma 2013 ·Sarcoma ·(unknown), Michael T. Selch, Pin‐Chieh Wang, Noah Federman, Jay M. Lee, Fritz C. Eilber, Bartosz Chmielowski, Nzhde Agazaryan, Michael L. Steinberg, Percy Lee	27
20	Long‐term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high‐grade, operable osteosarcoma 2012 ·Cancer ·Nicholas M. Bernthal, Noah Federman, Frederick R. Eilber, Scott D. Nelson, Jeffrey J. Eċkardt, Fritz C. Eilber, William D. Tap	131

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact